Macrolide immunomodulatory effects and symptom resolution in acute exacerbation of chronic bronchitis and acute maxillary sinusitis: a focus on clarithromycin

References

• McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA273(3), 214–219 (1995).
   PubMed Web of Science ®Google Scholar
• Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest108(2 Suppl.), 43S–52S (1995).
   PubMed Web of Science ®Google Scholar
• Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol. Head Neck Surg.123(1 Pt 2), 5–31 (2000).
   PubMed Web of Science ®Google Scholar
• Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J. Antimicrob. Chemother.43(Suppl. A), 97–105 (1999).
   PubMed Web of Science ®Google Scholar
• Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999–2000 respiratory surveillance program. Am. J. Med.111(Suppl. 9A), 19S–24S (2001).
   PubMed Web of Science ®Google Scholar
• Chan J, Hadley J. The microbiology of chronic rhinosinusitis: results of a community surveillance study. Ear Nose Throat J.80(3), 143–145 (2001).
   PubMedGoogle Scholar
• Black SB, Shinefield HR, Hansen J, Elvin L, Laufer D, Malinoski F. Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J.20(12), 1105–1107 (2001).
   PubMed Web of Science ®Google Scholar
• Swords WE, Rubin BK. Macrolide antibiotics, bacterial populations and inflammatory airway disease. Neth. J. Med.61(7), 242–248 (2003).
   PubMed Web of Science ®Google Scholar
• Cervin A, Wallwork B. Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis. Otolaryngol. Clin. North Am.38(6), 1339–1350 (2005).
   PubMed Web of Science ®Google Scholar
• Chinali G, Nyssen E, Di Giambattista M, Cocito C. Inhibition of polypeptide synthesis in cell-free systems by virginiamycin S and erythromycin. Evidence for a common mode of action of type B synergimycins and 14-membered macrolides. Biochim. Biophys. Acta949(1), 71–78 (1988).
   PubMed Web of Science ®Google Scholar
• Rubin BK, Henke MO. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest125(2 Suppl.), 70S–78S (2004).
   PubMed Web of Science ®Google Scholar
• Shinkai M, Rubin BK. Macrolides and airway inflammation in children. Paediatr. Respir. Rev.6(3), 227–235 (2005).
   PubMedGoogle Scholar
• Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am. J. Med.117(Suppl. 9A), 5S–11S (2004).
   PubMed Web of Science ®Google Scholar
• Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest125(2 Suppl.), 52S–60S (2004).
   PubMedGoogle Scholar
• Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest125(2 Suppl.), 62S–69S (2004).
   PubMed Web of Science ®Google Scholar
• Murray PR, Rosenthal KS, Pfaller MA. Medical Microbiology. 5th Edition. Elsevier Mosby, PA, USA (2005).
   Google Scholar
• Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med.99(6A), 26S–30S (1995).
   Web of Science ®Google Scholar
• Kikuchi T, Hagiwara K, Honda Y et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J. Antimicrob. Chemother.49(5), 745–755 (2002).
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Takeyama K, Yamawaki I, Kondo M, Konno K. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am. J. Physiol.272(1 Pt 1), L15–L19 (1997).
   Google Scholar
• Tamaoki J, Nakata J, Tagaya E, Konno K. Effects of roxithromycin and erythromycin on interleukin 8-induced neutrophil recruitment and goblet cell secretion in guinea pig tracheas. Antimicrob. Agents Chemother.40(7), 1726–1728 (1996).
   PubMed Web of Science ®Google Scholar
• Fujita K, Shimizu T, Majima Y, Sakakura Y. Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur. Arch. Otorhinolaryngol.257(4), 199–204 (2000).
   PubMed Web of Science ®Google Scholar
• Kawasaki S, Koyama T, Takami K, Takizawa H, Nakamura H, Ito K. [Effects of a steroid and macrolide antibiotic on adhesion of neutrophils to the airway epithelial cells]. Jpn J. Antibiot.51(Suppl. A), 43–45 (1998).
   PubMedGoogle Scholar
• MacLeod CM, Hamid QA, Cameron L, Tremblay C, Brisco W. Anti-inflammatory activity of clarithromycin in adults with chronically inflamed sinus mucosa. Adv. Ther.18(2), 75–82 (2001).
   PubMed Web of Science ®Google Scholar
• Wallwork B, Coman W, Feron F, Mackay-Sim A, Cervin A. Clarithromycin and prednisolone inhibit cytokine production in chronic rhinosinusitis. Laryngoscope112(10), 1827–1830 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Shimomura A, Ikeda K, Oshima T, Takasaka T. Effects of long-term low-dose macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J. Exp. Med.182(2), 115–124 (1997).
   PubMed Web of Science ®Google Scholar
• Ichiyama T, Nishikawa M, Yoshitomi T et al. Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob. Agents Chemother.45(1), 44–47 (2001).
   PubMed Web of Science ®Google Scholar
• Aoki Y, Kao PN. Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob. Agents Chemother.43(11), 2678–2684 (1999).
   PubMed Web of Science ®Google Scholar
• Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation20(6), 693–705 (1996).
   PubMed Web of Science ®Google Scholar
• Braga PC, Maci S, Dal Sasso M, Fonti E, Ghessi A. Effects of rokitamycin on phagocytosis and release of oxidant radicals of human polymorphonuclear leukocytes. Chemotherapy43(3), 190–197 (1997).
   PubMed Web of Science ®Google Scholar
• Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am. J. Respir. Crit. Care Med.155(6), 2018–2023 (1997).
   PubMed Web of Science ®Google Scholar
• Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest122(1), 213–218 (2002).
   PubMed Web of Science ®Google Scholar
• Nishi K, Mizuguchi M, Tachibana H et al. [Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome]. Nihon Kyobu Shikkan Gakkai Zasshi33(12), 1392–1400 (1995).
   PubMedGoogle Scholar
• Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann. Otol. Rhinol. Laryngol.109(5), 484–487 (2000).
   PubMed Web of Science ®Google Scholar
• Tamaoki J, Tagaya E, Sakai A, Konno K. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J. Allergy Clin. Immunol.95(4), 853–859 (1995).
   PubMed Web of Science ®Google Scholar
• Takeyama K, Tamaoki J, Chiyotani A, Tagaya E, Konno K. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in-vitro. J. Pharm. Pharmacol.45(8), 756–758 (1993).
   PubMed Web of Science ®Google Scholar
• Nakano T, Ohashi Y, Tanaka A, Kakinoki Y, Washio Y, Nakai Y. Roxythromycin reinforces epithelial defence function in rabbit trachea. Acta Otolaryngol.538, 233–238 (1998).
   Google Scholar
• Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet360(9338), 978–984 (2002).
   PubMed Web of Science ®Google Scholar
• Pirzada OM, McGaw J, Taylor CJ, Everard ML. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J. Cyst. Fibros.2(2), 69–71 (2003).
   PubMedGoogle Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA290(13), 1749–1756 (2003).
   PubMed Web of Science ®Google Scholar
• Wolter JM, Seeney SL, McCormack JG. Macrolides in cystic fibrosis: is there a role? Am. J. Respir. Med.1(4), 235–241 (2002).
   PubMedGoogle Scholar
• Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr. Pulmonol.31(6), 464–473 (2001).
   PubMed Web of Science ®Google Scholar
• Anstead MI, Kuhn LH, Craigmyle L, Halsey S, Kanga JF. Effect of chronic azithromycin on lung function in cystic fibrosis. Pediatr. Pulmonol.19, 283–284 (1999).
   Google Scholar
• Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax57(3), 212–216 (2002).
   PubMed Web of Science ®Google Scholar
• Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm.13(2), 111–117 (2004).
   PubMed Web of Science ®Google Scholar
• Baumann U, King M, App EM et al. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J.11(2), 151–155 (2004).
   PubMedGoogle Scholar
• Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax42(10), 773–778 (1987).
   PubMed Web of Science ®Google Scholar
• Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology11(3), 249–261 (2006).
   PubMed Web of Science ®Google Scholar
• Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am. J. Respir. Crit. Care Med.157(6 Pt 1), 1829–1832 (1998).
   PubMed Web of Science ®Google Scholar
• Kadota J, Mukae H, Ishii H et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir. Med.97(7), 844–850 (2003).
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest107(1), 120–125 (1995).
   PubMed Web of Science ®Google Scholar
• Ashitani J, Mukae H, Nakazato M et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur. Respir. J.11(1), 104–111 (1998).
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Ninomiya H, Koga H et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am. Rev. Respir. Dis.146(1), 196–203 (1992).
   PubMed Web of Science ®Google Scholar
• Hiratsuka T, Mukae H, Iiboshi H et al. Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax58(5), 425–430 (2003).
   PubMed Web of Science ®Google Scholar
• Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest118(6), 1826–1827 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenberg SM, Gerhard H, Grunstein MM, Schramm CM. Use of TAO without methylprednisolone in the treatment of severe asthma. Chest100(3), 849–850 (1991).
   PubMed Web of Science ®Google Scholar
• Spector SL, Katz FH, Farr RS. Troleandomycin: effectiveness in steroid dependent asthma and bronchitis. J. Allergy Clin. Immunol.54, 367–369 (1974).
   Web of Science ®Google Scholar
• Mestecky J, Bienenstock J. Mucosal Immunology. 3rd Edition. Elsevier Academic Press, Amsterdam, The Netherlands (2005).
   Google Scholar
• Shimizu T, Kato M, Mochizuki H et al. Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J. Asthma34(3), 211–217 (1997).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest106(2), 458–461 (1994).
   PubMed Web of Science ®Google Scholar
• Miyatake H, Suzuki K, Taki F, Takagi K, Satake T. Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung41(5), 552–556 (1991).
   PubMed Web of Science ®Google Scholar
• Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest99(3), 670–673 (1991).
   PubMed Web of Science ®Google Scholar
• Amayasu H, Yoshida S, Ebana S et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann. Allergy Asthma Immunol.84(6), 594–598 (2000).
   PubMed Web of Science ®Google Scholar
• Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J. Asthma32(3), 191–197 (1995).
   PubMed Web of Science ®Google Scholar
• Konno S, Asano K, Kurokawa M, Ikeda K, Okamoto K, Adachi M. Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int. Arch. Allergy Immunol.105(3), 308–316 (1994).
   PubMed Web of Science ®Google Scholar
• Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation77(9), 1465–1467 (2004).
   PubMed Web of Science ®Google Scholar
• Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR. Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J. Heart Lung Transplant.24(9), 1440–1443 (2005).
   PubMed Web of Science ®Google Scholar
• Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother.55(1), 10–21 (2005).
   PubMed Web of Science ®Google Scholar
• Chow LW, Yuen KY, Woo PC, Wei WI. Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clin. Diagn. Lab. Immunol.7(6), 925–931 (2000).
   PubMedGoogle Scholar
• Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect. Dis.3(6), 359–371 (2003).
   PubMed Web of Science ®Google Scholar
• Guay DR, Gustavson LE, Devcich KJ, Zhang J, Cao G, Olson CA. Pharmacokinetics and tolerability of extended-release clarithromycin. Clin. Ther.23(4), 566–577 (2001).
   PubMed Web of Science ®Google Scholar
• Adler JL, Jannetti W, Schneider D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis. Clin. Ther.22(12), 1410–1420 (2000).
   PubMed Web of Science ®Google Scholar
• Nalepa P, Dobryniewska M, Busman T, Notario G. Short-course therapy of acute bacterial exacerbation of chronic bronchitis: a double-blind, randomized, multicenter comparison of extended-release versus immediate-release clarithromycin. Curr. Med. Res. Opin.19(5), 411–420 (2003).
   PubMed Web of Science ®Google Scholar
• Gotfried M, Notario G, Spiller J, Palmer R, Busman T. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis. Curr. Med. Res. Opin.21(2), 245–254 (2005).
   PubMed Web of Science ®Google Scholar
• Weiss LR. Open-label, randomized comparison of the efficacy and tolerability of clarithromycin, levofloxacin, and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin. Ther.24(9), 1414–1425 (2002).
   PubMed Web of Science ®Google Scholar
• Murray JJ, Solomon E, McCluskey D, Zhang J, Palmer R, Notario G. Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis. Clin. Ther.22(12), 1421–1432 (2000).
   PubMed Web of Science ®Google Scholar
• Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. Treatment cost of acute exacerbations of chronic bronchitis. Clin. Ther.21(3), 576–591 (1999).
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med.153(5), 1530–1535 (1996).
   PubMed Web of Science ®Google Scholar
• Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis: executive summary. Can. Respir. J.10(5), 248–258 (2003).
   PubMedGoogle Scholar
• Celli BR, Snider GL, Heffner J. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.152(Suppl.), 77–120 (1995).
   PubMed Web of Science ®Google Scholar
• Grossman RF. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest112(6 Suppl.), 310S–313S (1997).
   Google Scholar
• Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest117(5 Suppl. 2), 380S–385S (2000).
   Google Scholar
• Mulder J, Goslings WR, Van Der Plas MC, Cardozo PL. Studies on the treatment with antibacterial drugs of acute and chronic mucopurulent bronchitis caused by Hemophilus influenzae. Acta Med. Scand.143(1), 32–49 (1952).
   PubMedGoogle Scholar
• Lees AW, Mcnaught W. Bacteriology of lower-respiratory-tract secretions, sputum, and upper-respiratory-tract secretions in ‘normals’ and chronic bronchitics. Lancet2, 1112–1115 (1959).
   PubMed Web of Science ®Google Scholar
• Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin. Respir. Infect.15(1), 59–70 (2000).
   PubMedGoogle Scholar
• Fendrick AM, Saint S, Brook I, Jacobs MR, Pelton S, Sethi S. Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin. Ther.23(10), 1683–1706 (2001).
   PubMed Web of Science ®Google Scholar
• Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA273(12), 957–960 (1995).
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med.106(2), 196–204 (1987).
   PubMed Web of Science ®Google Scholar
• Wilson R, Tillotson G, Ball P. Clinical studies in chronic bronchitis: a need for better definition and classification of severity. J. Antimicrob. Chemother.37(2), 205–208 (1996).
   PubMed Web of Science ®Google Scholar
• Balter MS, La Forge J, Low DE, Mandell L, Grossman RF. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can. Respir. J.10(Suppl. B), 3B–32B (2003).
   PubMedGoogle Scholar
• Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J.26(6), 1138–1180 (2005).
   PubMed Web of Science ®Google Scholar
• Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin. Ther.23(1), 97–107 (2001).
   PubMed Web of Science ®Google Scholar
• Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther.24(4), 639–652 (2002).
   PubMed Web of Science ®Google Scholar
• Anzueto A, Fisher CL Jr, Busman T, Olson CA. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin/clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther.23(1), 72–86 (2001).
   PubMed Web of Science ®Google Scholar
• Gwaltney JM Jr, Wiesinger BA, Patrie JT. Acute community-acquired bacterial sinusitis: the value of antimicrobial treatment and the natural history. Clin. Infect. Dis.38(2), 227–233 (2004).
   PubMed Web of Science ®Google Scholar
• Carenfelt C, Melen I, Odkvist L et al. Treatment of sinus empyema in adults. A coordinated Nordic multicenter trial of cefixime vs. cefaclor. Acta Otolaryngol.110(1–2), 128–135 (1990).
   PubMed Web of Science ®Google Scholar
• Carenfelt C, Eneroth CM, Lundberg C, Wretlind B. Evaluation of the antibiotic effect of treatment of maxillary sinusitis. Scand. J. Infect. Dis.7(4), 259–264 (1975).
   PubMed Web of Science ®Google Scholar
• Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J. Allergy Clin. Immunol.90(3 Pt 2), 457–461 (1992).
   PubMed Web of Science ®Google Scholar
• Hamory BH, Sande MA, Sydnor A Jr, Seale DL, Gwaltney JM Jr. Etiology and antimicrobial therapy of acute maxillary sinusitis. J. Infect. Dis.139(2), 197–202 (1979).
   PubMed Web of Science ®Google Scholar
• Adelglass J, Jones TM, Ruoff G et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy18(6), 1255–1263 (1998).
   PubMed Web of Science ®Google Scholar
• Clifford K, Huck W, Shan M, Tosiello R, Echols RM, Heyd A. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. Ann. Otol. Rhinol. Laryngol.108(4), 360–367 (1999).
   PubMed Web of Science ®Google Scholar
• Henry DC, Moller DJ Jr, Adelglass J et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. Clin. Ther.21(2), 340–352 (1999).
   PubMed Web of Science ®Google Scholar
• Lasko B, Lau CY, Saint-Pierre C, Reddington JL, Martel A, Anstey RJ. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized study. The Canadian Sinusitis Study Group. J. Int. Med. Res.26(6), 281–291 (1998).
   PubMed Web of Science ®Google Scholar
• Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J.72(12), 804–810 (1993).
   PubMedGoogle Scholar
• Riffer E, Spiller J, Palmer R, Shortridge V, Busman TA, Valdes J. Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr. Med. Res. Opin.21(1), 61–70 (2005).
   PubMed Web of Science ®Google Scholar
• Corey JP, Kemker BJ, Branca JT, Kuo F, Chang Y, Gliklich RE. Health status in allergic rhinitis. Otolaryngol. Head Neck Surg.122(5), 681–685 (2000).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin. Exp. Allergy21(1), 77–83 (1991).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30(6), 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Rechtweg JS, Moinuddin R, Houser SM, Mamikoglu B, Corey JP. Quality of life in treatment of acute rhinosinusitis with clarithromycin and amoxicillin/clavulanate. Laryngoscope114(5), 806–810 (2004).
   PubMed Web of Science ®Google Scholar
• Mitsuya Y, Kawai S, Kobayashi H. Influence of macrolides on guanosine diphospho-d-mannose dehydrogenase activity in Pseudomonas biofilm. J. Infect. Chemother.6(1), 45–50 (2000).
   PubMedGoogle Scholar
• Imamura Y, Yanagihara K, Mizuta Y et al. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob. Agents Chemother.48(9), 3457–3461 (2004).
   PubMed Web of Science ®Google Scholar
• Matsui H, Eguchi M, Ohsumi K et al. Azithromycin inhibits the formation of flagellar filaments without suppressing flagellin synthesis in Salmonella enterica serovar typhimurium. Antimicrob. Agents Chemother.49(8), 3396–3403 (2005).
   PubMed Web of Science ®Google Scholar
• Tateda K, Standiford TJ, Pechere JC, Yamaguchi K. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr. Pharm. Des.10(25), 3055–3065 (2004).
   PubMed Web of Science ®Google Scholar
• Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob. Agents Chemother.34(5), 863–870 (1990).
   PubMed Web of Science ®Google Scholar
• Nadel JA, Takeyama K, Agusti C. Role of neutrophil elastase in hypersecretion in asthma. Eur. Respir. J.13(1), 190–196 (1999).
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Shimizu T, Sakakura Y. Effects of indomethacin, dexamethasone, and erythromycin on endotoxin-induced intraepithelial mucus production of rat nasal epithelium. Ann. Otol. Rhinol. Laryngol.106(8), 683–687 (1997).
   PubMed Web of Science ®Google Scholar